Articles with public access mandates - Christos SotiriouLearn more
Not available anywhere: 11
Review
Clinical relevance of host immunity in breast cancer: from TILs to the clinic
P Savas, R Salgado, C Denkert, C Sotiriou, PK Darcy, MJ Smyth, S Loi
Nature reviews Clinical oncology 13 (4), 228-241, 2016
Mandates: National Health and Medical Research Council, Australia, Susan G. Komen
Review
Molecular profiling: moving away from tumor philately
JS Reis-Filho, B Weigelt, D Fumagalli, C Sotiriou
Science translational medicine 2 (47), 47ps43-47ps43, 2010
Mandates: Cancer Research UK
Review
CD73 promotes resistance to HER2/ErbB2 antibody therapy
M Turcotte, D Allard, D Mittal, Y Bareche, L Buisseret, V José, S Pommey, ...
Cancer research 77 (20), 5652-5663, 2017
Mandates: National Health and Medical Research Council, Australia, National Fund for …
Review
Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: a meta …
C Solinas, M Ceppi, M Lambertini, M Scartozzi, L Buisseret, S Garaud, ...
Cancer treatment reviews 57, 8-15, 2017
Mandates: National Fund for Scientific Research, Belgium
Review
Infrared imaging in breast cancer: automated tissue component recognition and spectral characterization of breast cancer cells as well as the tumor microenvironment
A Benard, C Desmedt, M Smolina, P Szternfeld, M Verdonck, G Rouas, ...
Analyst 139 (5), 1044-1056, 2014
Mandates: National Fund for Scientific Research, Belgium
Review
Genomic Grade Index: An important tool for assessing breast cancer tumor grade and prognosis
O Metzger Filho, M Ignatiadis, C Sotiriou
Critical reviews in oncology/hematology 77 (1), 20-29, 2011
Mandates: US National Institutes of Health
Review
Differential benefit of adjuvant docetaxel-based chemotherapy in patients with early breast cancer according to baseline body mass index
C Desmedt, M Fornili, F Clatot, R Demicheli, D De Bortoli, A Di Leo, ...
Journal of Clinical Oncology 38 (25), 2883-2891, 2020
Mandates: AIRC Foundation for Cancer Research in Italy
Review
Loss of ARID1A activates ANXA1, which serves as a predictive biomarker for trastuzumab resistance
K Berns, A Sonnenblick, A Gennissen, S Brohée, EM Hijmans, B Evers, ...
Clinical Cancer Research 22 (21), 5238-5248, 2016
Mandates: Netherlands Organisation for Scientific Research, Dutch Cancer Society
Review
Transcriptomic and genomic features of invasive lobular breast cancer
C Desmedt, G Zoppoli, C Sotiriou, R Salgado
Seminars in cancer biology 44, 98-105, 2017
Mandates: Susan G. Komen
Review
Absence of ESR1 amplification in a series of breast cancers
J Adélaïde, P Finetti, E Charafe‐Jauffret, J Wicinski, J Jacquemier, ...
International journal of cancer 123 (12), 2970-2972, 2008
Mandates: National Institute of Health and Medical Research, France
Review
Integrated molecular and immune phenotype of HER2-positive breast cancer and response to neoadjuvant therapy: a NeoALTTO exploratory analysis
S Pizzamiglio, CM Ciniselli, T Triulzi, C Gargiuli, L De Cecco, ...
Clinical Cancer Research 27 (23), 6307-6313, 2021
Mandates: AIRC Foundation for Cancer Research in Italy
Available somewhere: 169
Review
Landscape of somatic mutations in 560 breast cancer whole-genome sequences
S Nik-Zainal, H Davies, J Staaf, M Ramakrishna, D Glodzik, X Zou, ...
Nature 534 (7605), 47-54, 2016
Mandates: US Department of Energy, US National Institutes of Health, National Fund for …
Review
Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group
M Dowsett, TO Nielsen, R A’Hern, J Bartlett, RC Coombes, J Cuzick, ...
Journal of the National cancer Institute 103 (22), 1656-1664, 2011
Mandates: Cancer Research UK
Review
The landscape of cancer genes and mutational processes in breast cancer
PJ Stephens, PS Tarpey, H Davies, P Van Loo, C Greenman, DC Wedge, ...
Nature 486 (7403), 400-404, 2012
Mandates: US National Institutes of Health, Research Foundation (Flanders), National …
Review
70-gene signature as an aid to treatment decisions in early-stage breast cancer
F Cardoso, LJ van’t Veer, J Bogaerts, L Slaets, G Viale, S Delaloge, ...
New England Journal of Medicine 375 (8), 717-729, 2016
Mandates: US National Institutes of Health, Cancer Research UK, Dutch Cancer Society …
Review
Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial
S Loi, S Michiels, R Salgado, N Sirtaine, V Jose, D Fumagalli, ...
Annals of oncology 25 (8), 1544-1550, 2014
Mandates: National Health and Medical Research Council, Australia, Susan G. Komen
Review
Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2–positive and triple-negative …
C Denkert, G Von Minckwitz, JC Brase, BV Sinn, S Gade, R Kronenwett, ...
Journal of clinical oncology 33 (9), 983-991, 2015
Mandates: European Commission
Review
HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures
H Davies, D Glodzik, S Morganella, LR Yates, J Staaf, X Zou, ...
Nature medicine 23 (4), 517-525, 2017
Mandates: US National Institutes of Health, Netherlands Organisation for Scientific …
Review
Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes
C Desmedt, B Haibe-Kains, P Wirapati, M Buyse, D Larsimont, ...
Clinical cancer research 14 (16), 5158-5165, 2008
Mandates: Swiss National Science Foundation
Review
The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models
L Shi, G Campbell, WD Jones, F Campagne, Z Wen, SJ Walker, Z Su, ...
Nature biotechnology 28 (8), 827-838, 2010
Mandates: US National Institutes of Health
Publication and funding information is determined automatically by a computer program